Literature DB >> 17273938

A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations.

Yingting Liu1, Jeremy Purvis, Andrew Shih, Joshua Weinstein, Neeraj Agrawal, Ravi Radhakrishnan.   

Abstract

We describe a hierarchical multiscale computational approach based on molecular dynamics simulations, free energy-based molecular docking simulations, deterministic network-based kinetic modeling, and hybrid discrete/continuum stochastic dynamics protocols to study the dimer-mediated receptor activation characteristics of the Erb family receptors, specifically the epidermal growth factor receptor (EGFR). Through these modeling approaches, we are able to extend the prior modeling of EGF-mediated signal transduction by considering specific EGFR tyrosine kinase (EGFRTK) docking interactions mediated by differential binding and phosphorylation of different C-terminal peptide tyrosines on the RTK tail. By modeling signal flows through branching pathways of the EGFRTK resolved on a molecular basis, we are able to transcribe the effects of molecular alterations in the receptor (e.g., mutant forms of the receptor) to differing kinetic behavior and downstream signaling response. Our molecular dynamics simulations show that the drug sensitizing mutation (L834R) of EGFR stabilizes the active conformation to make the system constitutively active. Docking simulations show preferential characteristics (for wildtype vs. mutant receptors) in inhibitor binding as well as preferential enhancement of phosphorylation of particular substrate tyrosines over others. We find that in comparison to the wildtype system, the L834R mutant RTK preferentially binds the inhibitor erlotinib, as well as preferentially phosphorylates the substrate tyrosine Y1068 but not Y1173. We predict that these molecular level changes result in preferential activation of the Akt signaling pathway in comparison to the Erk signaling pathway for cells with normal EGFR expression. For cells with EGFR over expression, the mutant over activates both Erk and Akt pathways, in comparison to wildtype. These results are consistent with qualitative experimental measurements reported in the literature. We discuss these consequences in light of how the network topology and signaling characteristics of altered (mutant) cell lines are shaped differently in relationship to native cell lines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17273938      PMCID: PMC3021414          DOI: 10.1007/s10439-006-9251-0

Source DB:  PubMed          Journal:  Ann Biomed Eng        ISSN: 0090-6964            Impact factor:   3.934


  69 in total

Review 1.  Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases.

Authors:  H Waterman; Y Yarden
Journal:  FEBS Lett       Date:  2001-02-16       Impact factor: 4.124

2.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Fontanini; S Cuccato; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

3.  A unified polymerase mechanism for nonhomologous DNA and RNA polymerases.

Authors:  T A Steitz; S J Smerdon; J Jäger; C M Joyce
Journal:  Science       Date:  1994-12-23       Impact factor: 47.728

4.  VMD: visual molecular dynamics.

Authors:  W Humphrey; A Dalke; K Schulten
Journal:  J Mol Graph       Date:  1996-02

Review 5.  Clathrin-coated vesicle formation and protein sorting: an integrated process.

Authors:  S L Schmid
Journal:  Annu Rev Biochem       Date:  1997       Impact factor: 23.643

6.  Differential inhibition of epidermal growth factor signaling pathways in rat hepatocytes by long-term ethanol treatment.

Authors:  K Saso; G Moehren; K Higashi; J B Hoek
Journal:  Gastroenterology       Date:  1997-06       Impact factor: 22.682

Review 7.  A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

Authors:  F Ciardiello; G Tortora
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

8.  Catalytic specificity of protein-tyrosine kinases is critical for selective signalling.

Authors:  Z Songyang; K L Carraway; M J Eck; S C Harrison; R A Feldman; M Mohammadi; J Schlessinger; S R Hubbard; D P Smith; C Eng
Journal:  Nature       Date:  1995-02-09       Impact factor: 49.962

Review 9.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

Review 10.  The EGF receptor family as targets for cancer therapy.

Authors:  J Mendelsohn; J Baselga
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

View more
  17 in total

Review 1.  Structural systems biology and multiscale signaling models.

Authors:  Shannon E Telesco; Ravi Radhakrishnan
Journal:  Ann Biomed Eng       Date:  2012-04-27       Impact factor: 3.934

2.  Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype.

Authors:  Shannon E Telesco; Rajanikanth Vadigepalli; Ravi Radhakrishnan
Journal:  Biotechnol J       Date:  2013-12-04       Impact factor: 4.677

3.  In silico prediction of ErbB signal activation from receptor expression profiles through a data analytics pipeline.

Authors:  Arya A Das; Elizabeth Jacob
Journal:  J Biosci       Date:  2018-06       Impact factor: 1.826

4.  A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network.

Authors:  Shannon E Telesco; Andrew J Shih; Fei Jia; Ravi Radhakrishnan
Journal:  Mol Biosyst       Date:  2011-04-20

5.  Computational delineation of tyrosyl-substrate recognition and catalytic landscapes by the epidermal growth factor receptor tyrosine kinase domain.

Authors:  Yingting Liu; Ravi Radhakrishnan
Journal:  Mol Biosyst       Date:  2014-04-29

6.  PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations.

Authors:  Parminder K Mankoo; Saraswati Sukumar; Rachel Karchin
Journal:  Proteins       Date:  2009-05-01

7.  Quantitative prediction of fold resistance for inhibitors of EGFR.

Authors:  Trent E Balius; Robert C Rizzo
Journal:  Biochemistry       Date:  2009-09-08       Impact factor: 3.162

8.  Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing.

Authors:  Andrew J Shih; Jeremy Purvis; Ravi Radhakrishnan
Journal:  Mol Biosyst       Date:  2008-09-12

9.  Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancer.

Authors:  Jeremy Purvis; Vibitha Ilango; Ravi Radhakrishnan
Journal:  Biotechnol Prog       Date:  2008-04-16

10.  Cancer Cell: Linking Oncogenic Signaling to Molecular Structure.

Authors:  Jeremy E Purvis; Andrew J Shih; Yingting Liu; Ravi Radhakrishnan
Journal:  Chapman Hall CRC Math Comput Biol Ser       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.